Related Experiment Video

Updated: Mar 14, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis

Karn Wijarnpreecha1, Charat Thongprayoon, Patompong Ungprasert

  • 1aDepartment of Internal Medicine, Bassett Medical Center, Cooperstown, New York bDepartment of Internal Medicine, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA cDepartment of Medicine, Division of Rheumatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

European Journal of Gastroenterology & Hepatology
|September 28, 2016
PubMed

Insights

Regular caffeine consumption may reduce the risk of advanced liver fibrosis and inflammation in patients with Hepatitis C virus (HCV) infection. Further research is needed to confirm caffeine

Area of Science:

  • Hepatology and viral gastroenterology.
  • Nutritional science and its impact on liver health.

Background:

  • Hepatitis C virus (HCV) infection is a leading cause of cirrhosis.
  • Previous studies suggest a link between caffeine intake and reduced liver fibrosis/inflammation in HCV patients, but findings are inconsistent.
  • The impact of caffeine consumption on HCV progression requires clarification.

Purpose of the Study:

  • To assess the effect of regular caffeine consumption on liver fibrosis and inflammation in patients with HCV infection.
  • To synthesize existing evidence through a meta-analysis.

Main Methods:

  • Systematic literature search of MEDLINE and EMBASE databases up to January 2016.
  • Inclusion of studies reporting risk ratios (RR), odds ratios (OR), or hazard ratios (HR) for advanced liver fibrosis or moderate-to-severe inflammation in regular caffeine consumers versus non-consumers.
  • Meta-analysis using a random-effect, generic inverse-variance method to calculate pooled ORs and 95% confidence intervals (CIs).

Main Results:

  • Analysis of 5 studies revealed a pooled OR of 0.48 (95% CI, 0.30-0.76) for advanced liver fibrosis in regular caffeine consumers.
  • Analysis of 3 studies showed a pooled OR of 0.61 (95% CI, 0.35-1.04) for moderate to severe liver inflammation in regular caffeine consumers.
  • Results indicate a statistically significant reduction in advanced liver fibrosis risk.

Conclusions:

  • Regular caffeine consumption is associated with a reduced risk of advanced liver fibrosis and liver inflammation in HCV-infected patients.
  • The findings suggest a potential role for caffeine in managing HCV infection, warranting further investigation.
Abstract

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K
Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

21.6K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
324
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
310
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
277
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
704
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
648